Bigger Is Better, FDA Tells J&J Over Invokana Outcomes Trial
This article was originally published in Pharmaceutical Approvals Monthly
Because of its preference for a strict MACE endpoint, rather than MACE+, for post-market cardiovascular outcomes trials of anti-diabetics, FDA thought J&J’s ongoing canagliflozin trial would take too long to reach the number of events needed due to its size. So J&J will start a new outcomes trial, bringing Invokana’s CVOT total enrollment to 10,000.
You may also be interested in...
Even in the grip of the pandemic, review times for priority drugs were also consistent with the last three years.
Influence of expedited review pathways and regulatory incentives is on display in 2020’s novel approvals, which have a composition reassuringly consistent with recent years.
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker